These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26632514)

  • 1. Decreased levels of procoagulant phospholipids in bleeding patients treated by vitamin K antagonists.
    Mathieu E; Van Dreden P; Aulagnier J; Grusse M; Dreyfus JF; François D; Vasse M
    Thromb Res; 2016 Jan; 137():36-40. PubMed ID: 26632514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.
    Rousseau A; Woodhams B; Paunet-Bobo M; Van Dreden P; Bigot D; Leclerc S; Lenormand B; Vasse M
    Thromb Res; 2012 Sep; 130(3):491-4. PubMed ID: 22551976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of vitamin K antagonist overcoagulation.
    Marie I; Leprince P; Menard JF; Tharasse C; Levesque H
    QJM; 2012 Jan; 105(1):53-62. PubMed ID: 21880698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversing vitamin K antagonists: making the old new again.
    Eichinger S
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):605-611. PubMed ID: 27913535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients.
    Karrowni W; Wang TY; Chen AY; Thomas L; Saucedo JF; El Accaoui RN
    Heart; 2015 Feb; 101(4):264-70. PubMed ID: 25336230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding).
    Pernod G; Godiér A; Gozalo C; Tremey B; Sié P;
    Thromb Res; 2010 Sep; 126(3):e167-74. PubMed ID: 20630568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K antagonists and emergencies.
    Lapostolle F; Siguret V; Martin AC; Pailleret C; Vigué B; Zerbib Y; Tazarourte K
    Eur J Emerg Med; 2018 Dec; 25(6):378-386. PubMed ID: 29462053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.
    Cadiou G; Varin R; Levesque H; Grassi V; Benichou J; Tiret I; Dieu B; Lecam-Duchez V; Borg JY; Muller JM; Benhamou Y; Marie I
    Thromb Haemost; 2008 Oct; 100(4):685-92. PubMed ID: 18841293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome.
    Isert M; Miesbach W; Schüttfort G; Weil Y; Tirneci V; Kasper A; Weber A; Lindhoff-Last E; Herrmann E; Linnemann B
    Ann Hematol; 2015 Aug; 94(8):1291-9. PubMed ID: 25859986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
    Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
    Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bleeding secondary to vitamin K antagonist treatment: adaptation of the International Normalized Ratio (INR) determination during high hypertriglyceridemia].
    Miot S; Marteau AT; Simard G; Lavigne C
    Rev Med Interne; 2010 Jan; 31(1):60-2. PubMed ID: 19201067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study.
    Toorop MMA; van Rein N; Cannegieter SC; van der Meer FJM; Reitsma PH; Lijfering WM; Bos MHA
    Thromb Haemost; 2021 Jan; 121(1):70-75. PubMed ID: 32854121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
    Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
    J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.
    Mearns ES; Kohn CG; Song JS; Hawthorne J; Meng J; White CM; Raut MK; Schein JR; Coleman CI
    Thromb Res; 2014 Aug; 134(2):310-9. PubMed ID: 24935672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to optimal dosing of vitamin K antagonists.
    Witt DM
    Semin Thromb Hemost; 2012 Oct; 38(7):667-72. PubMed ID: 22893509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?
    Steib A; Barre J; Mertes M; Morel MH; Nathan N; Ozier Y; Treger M; Samama CM
    J Thromb Haemost; 2010 Mar; 8(3):499-503. PubMed ID: 19912513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.